Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve

Inclusion Criteria: * Patients ≥ 18 years old with BAV confirmed by transthoracic echocardiography (in case of doubts other techniques will be required: transesophageal echocardiography or CT to confirm diagnosis). * Valve dysfunction only moderate: in case of aortic stenosis with average gradient \< 30 mmHg and in case of aortic regurgitation a vena contracta \< 7 mm or a jet with \< 10 mm. * Aortic valve not show severe calcification by transthoracic echocardiography. * Ascending aortic diameter (Valsalva sinus or tubular ascending aorta) ≤ 50 mm. * The patient must give the consent form signed. Exclusion Criteria: * Patients younger than 18. * Patients with uncontrolled hypertension and a history or risk of diabetes mellitus. * Patients who receive statins treatment or other lipid lowering drug or if they have indication to be treated according to the current clinical practice guidelines. * Previous cardiac surgery or any surgery of other segments of the aorta. * Previous aortic dissection and/or aortic coarctation. * NYHA functional class III or IV. * Presence or antecedent of liver failure (transaminase \> 2 fold the superior limit of normal levels according to local laboratory), renal failure (creatinine clearance \< 30ml/min or creatinine \> 2.5mg/dl), myopathy or creatine kinase levels \> 5 fold the superior limit of normality, or other gastrointestinal, hematologic or endocrine diseases or any other situation that according to the investigator criteria could affec…